Skip to main content
SpringerLink
Log in

Intravesical Chemotherapy

  • Chapter
  • First Online:
Bladder Tumors:

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

  • 809 Accesses

Abstract

The rationale for intravesical therapy is to maximize the exposure of tumors located in the bladder to therapeutic agents while limiting the systemic exposure. According to the American Urological Association (AUA), intravesical chemotherapy is recommended as a single immediate instillation after a transurethral resection of bladder tumor (TURBT) and also as 6–12-weekly prophylactic courses for intermediate risk tumors. We discuss the indications and practical aspects of administration of intravesical chemotherapy. The properties and side effects of various intravesical agents are also dealt with. Newer methods improving the efficacy of the intravesical drugs are also detailed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Au JL, Badalament RA, Wientjes MG et al (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93:597

    Article  CAS  PubMed  Google Scholar 

  • Babjuk M, Oosterlinck W, Sylvester R et al (2008) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54:303

    Article  PubMed  Google Scholar 

  • Bartoletti R, Cai T, Gacci M et al (2005) Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 66:726

    Article  PubMed  Google Scholar 

  • Belldegrun AS, Franklin JR, O’Donnell MA et al (1998) Superficial bladder cancer: the role of interferon-alpha. J Urol 159:1793

    Article  CAS  PubMed  Google Scholar 

  • Bercovich E, Deriu M, Manferrari F et al (1995) BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder. Arch Ital Urol Androl 67:257

    CAS  PubMed  Google Scholar 

  • Bouffioux C, van der Meijden A, Kurth KH et al (1992) Objective response of superficial bladder tumors to intravesical treatment (including review of response of marker lesions). Prog Clin Biol Res 378:29

    CAS  PubMed  Google Scholar 

  • Bouffioux C, Kurth KH, Bono A et al (1995) Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 153:934

    Article  CAS  PubMed  Google Scholar 

  • Brausi M, Campo B, Pizzocaro G et al (1998) Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology 51:506

    Article  CAS  PubMed  Google Scholar 

  • Burgues JP, Gomez L, Pontones JL et al (2007) A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids. Eur Urol 51:962

    Article  CAS  PubMed  Google Scholar 

  • Burk K, Kurth KH, Newling D (1989) Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer. Prog Clin Biol Res 303:423

    CAS  PubMed  Google Scholar 

  • Chen D, Song D, Wientjes MG et al (2003) Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res 9:363

    CAS  PubMed  Google Scholar 

  • Connor RJ, Anderson JM, Machemer T et al (2005) Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens. Urology 66:224

    Article  PubMed  Google Scholar 

  • Dalbagni G, Russo P, Sheinfeld J et al (2002) Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20:3193

    Article  CAS  PubMed  Google Scholar 

  • Dalbagni G, Russo P, Bochner B et al (2006) Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 24:2729

    Article  CAS  PubMed  Google Scholar 

  • de Groot AC, Conemans JM (1991) Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C. Contact Dermat 24:201

    Article  Google Scholar 

  • Di Stasi SM, Vespasiani G, Giannantoni A et al (1997) Electromotive delivery of mitomycin C into human bladder wall. Cancer Res 57:875

    PubMed  Google Scholar 

  • Di Stasi SM, Giannantoni A, Massoud R et al (1999) Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res 59:4912

    PubMed  Google Scholar 

  • Di Stasi SM, Giannantoni A, Stephen RL et al (2003) Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study. J Urol 170:777

    Article  PubMed  Google Scholar 

  • Eto H, Oka Y, Ueno K et al (1994) Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group. Cancer Chemother Pharmacol 35(Suppl):S46

    Article  PubMed  Google Scholar 

  • Fodor I, Timiryasova T, Denes B et al (2005) Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model. J Urol 173:604

    Article  CAS  PubMed  Google Scholar 

  • Gasion JP, Cruz JF (2006) Improving efficacy of intravesical chemotherapy. Eur Urol 50:225

    Article  CAS  PubMed  Google Scholar 

  • Glashan RW (1990) A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 144:658

    CAS  PubMed  Google Scholar 

  • Gontero P, Casetta G, Maso G et al (2004) Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 46:339

    Article  CAS  PubMed  Google Scholar 

  • Gontero P, Fiorito C, Lucca I et al (2008) New drugs currently available in non-muscle invasive bladder cancer: update on gemcitabine studies. Arch Ital Urol Androl 80:162

    PubMed  Google Scholar 

  • Grabnar I, Bogataj M, Mrhar A (2003) Influence of chitosan and polycarbophil on permeation of a model hydrophilic drug into the urinary bladder wall. Int J Pharm 256:167

    Article  CAS  PubMed  Google Scholar 

  • Hall MC, Chang SS, Dalbagni G et al (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314

    Article  PubMed  Google Scholar 

  • Hashimoto H, Tokunaka S, Sasaki M et al (1992) Dimethylsulfoxide enhances the absorption of chemotherapeutic drug instilled into the bladder. Urol Res 20:233

    Article  CAS  PubMed  Google Scholar 

  • Herr HW (1997) High-risk superficial bladder cancer: transurethral resection alone in selected patients with T1 tumor. Semin Urol Oncol 15:142

    CAS  PubMed  Google Scholar 

  • Horn Y, Eidelman A, Walach N et al (1985) Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis-platinum versus cis-platinum plus hyaluronidase. J Surg Oncol 28:304

    Article  CAS  PubMed  Google Scholar 

  • Hou JQ, He J, Wang XL et al (2006) Effect of small interfering RNA targeting survivin gene on biological behaviour of bladder cancer. Chin Med J (Engl) 119:1734

    CAS  Google Scholar 

  • Huland H, Kloppel G, Feddersen I et al (1990) Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Urol 144:68

    CAS  PubMed  Google Scholar 

  • Huncharek M, Kupelnick B (2004) The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 27:522

    Article  PubMed  Google Scholar 

  • Inoue K, Perrotte P, Wood CG et al (2000) Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res 6:4422

    CAS  PubMed  Google Scholar 

  • Inoue K, Wood CG, Slaton JW et al (2001) Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. Oncol Rep 8:955

    CAS  PubMed  Google Scholar 

  • Issell BF, Prout GR Jr, Soloway MS et al (1984) Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. Cancer 53:1025

    Article  CAS  PubMed  Google Scholar 

  • Kaasinen E, Rintala E, Hellstrom P et al (2002) Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 42:167

    Article  PubMed  Google Scholar 

  • Kalble T, Beer M, Mendoza E et al (1994) BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study. Urologe A 33:133

    CAS  PubMed  Google Scholar 

  • Kavoussi LR, Brown EJ, Ritchey JK et al (1990) Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest 85:62

    Article  CAS  PubMed  Google Scholar 

  • Kondo T, Onitsuka S, Ryoji O et al (1999) Analysis of prognostic factors related to primary superficial bladder cancer tumor recurrence in prophylactic intravesical epirubicin therapy. Int J Urol 6:178

    Article  CAS  PubMed  Google Scholar 

  • Kuppermann BD, Thomas EL, de Smet MD et al (2005) Safety results of two phase III trials of an intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am J Ophthalmol 140:585

    Article  CAS  PubMed  Google Scholar 

  • Lamm DL (1992) Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am 19:573

    CAS  PubMed  Google Scholar 

  • Lamm DL, Torti FM (1996) Bladder cancer, 1996. CA Cancer J Clin 46:93

    Article  CAS  PubMed  Google Scholar 

  • Lamm DL, Blumenstein BA, Crawford ED et al (1991) A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 325:1205

    Article  CAS  PubMed  Google Scholar 

  • Lamm DL, Riggs DR, Traynelis CL et al (1995) Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153:1444

    Article  CAS  PubMed  Google Scholar 

  • Lamm D, Colombel M, Persad R, Soloway M, Bohle A, Palou J, Witjes A, Akaza H, Buckley R, Brausi M (2008) Clinical practice recommendations for the management of non–muscle invasive bladder cancerE. European Urology Supplements 7(10):651–666

    Google Scholar 

  • Laufer M, Ramalingam S, Schoenberg MP et al (2003) Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 21:697

    Article  CAS  PubMed  Google Scholar 

  • Le Visage C, Rioux-Leclercq N, Haller M et al (2004) Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer. J Urol 171:1324

    Article  PubMed  Google Scholar 

  • Leakakos T, Ji C, Lawson G et al (2003) Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers. Cancer Chemother Pharmacol 51:445

    CAS  PubMed  Google Scholar 

  • Li D, Gan Y, Wientjes MG et al (2001) Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in bladder tissues and tumors. J Urol 166:2500

    Article  CAS  PubMed  Google Scholar 

  • Liu B, Zhang Y, Wang Z et al (2002) Single instillation of epirubicin for the prophylaxis of recurrent primary superficial bladder carcinoma. Zhonghua Wai Ke Za Zhi 40:112

    PubMed  Google Scholar 

  • Lundholm C, Norlen BJ, Ekman P et al (1996) A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 156:372

    Article  CAS  PubMed  Google Scholar 

  • Maffezzini M, Simonato A, Zanon M et al (1996) Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer. J Urol 155:91

    Article  CAS  PubMed  Google Scholar 

  • Maffezzini M, Campodonico F, Canepa G et al (2007) Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder. Eur Urol 51:956

    Article  CAS  PubMed  Google Scholar 

  • Maier U, Baumgartner G (1986) Mitomycin C plasma levels after intravesical instillation with and without hyaluronidase. J Urol 135:845

    CAS  PubMed  Google Scholar 

  • Malmstrom PU, Wijkstrom H, Lundholm C et al (1999) Five-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 161:1124

    Article  CAS  PubMed  Google Scholar 

  • Mohanty NK, Nayak RL, Vasudeva P et al (2008) Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience. Urol Oncol 26:616

    CAS  PubMed  Google Scholar 

  • Mosher DF (1984) Physiology of fibronectin. Annu Rev Med 35:561

    Article  CAS  PubMed  Google Scholar 

  • Naito K, Hisazumi H, Uchibayashi T et al (1991) Integral laser photodynamic treatment of refractory multifocal bladder tumors. J Urol 146:1541

    CAS  PubMed  Google Scholar 

  • Newling DW, Hetherington J, Sundaram SK et al (2001) The use of valrubicin for the chemoresection of superficial bladder cancer – a marker lesion study. Eur Urol 39:643

    Article  CAS  PubMed  Google Scholar 

  • Nieder AM, Brausi M, Lamm D et al (2005a) Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66:108

    Article  PubMed  Google Scholar 

  • Nieder AM, Sved PD, Stein JP et al (2005b) Cystoprostatectomy and orthotopic ileal neobladder reconstruction for management of bacille Calmette Guerin-induced bladder contractures. Urology 65:909

    Article  PubMed  Google Scholar 

  • Ning S, Fuessel S, Kotzsch M et al (2004) siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25:1065

    CAS  PubMed  Google Scholar 

  • O’Donnell MA (2005) Practical applications of intravesical chemotherapy and immunotherapy in high-risk patients with superficial bladder cancer. Urol Clin North Am 32:121

    Article  PubMed  Google Scholar 

  • Okamura K, Murase T, Obata K et al (1994) A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group. Cancer Chemother Pharmacol 35(Suppl):S31

    Article  PubMed  Google Scholar 

  • Okamura K, Kinukawa T, Tsumura Y et al (1998) A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur Urol 33:285

    Article  CAS  PubMed  Google Scholar 

  • Onrust SV, Lamb HM (1999) Valrubicin. Drugs Aging 15:69

    Article  CAS  PubMed  Google Scholar 

  • Onrust SV, Wiseman LR, Goa KL (1999) Epirubicin: a review of its intravesical use in superficial bladder cancer. Drugs Aging 15:307

    Article  CAS  PubMed  Google Scholar 

  • Oosterlinck W, Solsona E, Akaza H et al (2005) Low-grade Ta (noninvasive) urothelial carcinoma of the bladder. Urology 66:75

    Article  PubMed  Google Scholar 

  • Patterson AL, Greenberg RE, Weems L et al (2000) Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology 56:232

    Article  CAS  PubMed  Google Scholar 

  • Pawinski A, Sylvester R, Kurth KH et al (1996) A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156:1934

    Article  CAS  PubMed  Google Scholar 

  • Rajala P, Kaasinen E, Raitanen M et al (2002) Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study – FinnBladder III long-term result. J Urol 168:981

    Article  CAS  PubMed  Google Scholar 

  • Richie JP (1992) Intravesical chemotherapy. Treatment selection, techniques, and results. Urol Clin North Am 19:521

    CAS  PubMed  Google Scholar 

  • Rintala E, Jauhiainen K, Rajala P et al (1995) Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group. J Urol 154:2050

    Article  CAS  PubMed  Google Scholar 

  • Rintala E, Jauhiainen K, Kaasinen E et al (1996) Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group. J Urol 156:56

    Article  CAS  PubMed  Google Scholar 

  • Schiffelers RM, Ansari A, Xu J et al (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32:e149

    Article  PubMed  Google Scholar 

  • See WA, Xia Q (1992) Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. J Natl Cancer Inst 84:510

    Article  CAS  PubMed  Google Scholar 

  • Smith JA Jr, Labasky RF, Cockett AT et al (1999) Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 162:1697

    Article  PubMed  Google Scholar 

  • Steinberg G, Bahnson R, Brosman S et al (2000) Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 163:761

    Article  CAS  PubMed  Google Scholar 

  • Sternberg CN, Donat SM, Bellmunt J et al (2007) Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 69:62

    Article  PubMed  Google Scholar 

  • Stricker P, Pryor K, Nicholson T et al (1996) Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. Urology 48:957

    Article  CAS  PubMed  Google Scholar 

  • Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171:2186

    Article  PubMed  Google Scholar 

  • Sylvester RJ, van der Meijden AP, Witjes JA et al (2005a) Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174:86

    Article  CAS  PubMed  Google Scholar 

  • Sylvester RJ, van der Meijden A, Witjes JA et al (2005b) High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 66:90

    Article  PubMed  Google Scholar 

  • Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466

    Article  PubMed  Google Scholar 

  • Thrasher JB, Crawford ED (1992) Complications of intravesical chemotherapy. Urol Clin North Am 19:529

    CAS  PubMed  Google Scholar 

  • Torelli F, Catanzaro F, Conti G et al (2001) High-dose epirubicin in the prophylactic treatment of T1G2 superficial bladder tumors. Eur Urol 39(Suppl 2):11–14

    Article  CAS  PubMed  Google Scholar 

  • Torti FM, Shortliffe LD, Williams RD et al (1988) Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study. J Clin Oncol 6:476

    CAS  PubMed  Google Scholar 

  • Tsushima T, Miyaji Y, Noda M et al (1998) Absorption of epirubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. Urol Int 60:161

    Article  CAS  PubMed  Google Scholar 

  • Tyagi P, Li Z, Chancellor M et al (2004) Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res 21:832

    Article  CAS  PubMed  Google Scholar 

  • van der Heijden AG, Moonen PM, Cornel EB et al (2006) Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response. J Urol 176:1349

    Article  PubMed  Google Scholar 

  • van der Meijden AP, Brausi M, Zambon V et al (2001) Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. J Urol 166:476

    Article  PubMed  Google Scholar 

  • Verma UN, Surabhi RM, Schmaltieg A et al (2003) Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 9:1291

    CAS  PubMed  Google Scholar 

  • Werthman PE, Drazan KE, Rosenthal JT et al (1996) Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol 155:753

    Article  CAS  PubMed  Google Scholar 

  • Wientjes MG, Badalament RA, Au JL (1993) Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol 32:255

    Article  CAS  PubMed  Google Scholar 

  • Witjes JA, Hendricksen K (2008) Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol 53:45

    Article  PubMed  Google Scholar 

  • Witjes JA, vd Meijden AP, Witjes WP et al (1993) A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. Eur J Cancer 29A:1672

    Article  CAS  PubMed  Google Scholar 

  • Witjes JA, v d Meijden AP, Collette L et al (1998) Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 52:403

    Article  CAS  PubMed  Google Scholar 

  • Xia H, Mao Q, Paulson HL et al (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 20:1006

    Article  CAS  PubMed  Google Scholar 

  • Ye Z, Chen J, Zhang X et al (2001) Novel gelatin-adriamycin sustained drug release system for intravesical therapy of bladder cancer. J Tongji Med Univ 21:145

    Article  CAS  PubMed  Google Scholar 

  • Zein TA, Friedberg N, Kim H (1986) Bone marrow suppression after intravesical mitomycin C treatment. J Urol 136:459

    CAS  PubMed  Google Scholar 

  • Zou L, Zhang P, Luo C et al (2006) Mad1 suppresses bladder cancer cell proliferation by inhibiting human telomerase reverse transcriptase transcription and telomerase activity. Urology 67:1335

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Miller School of Medicine, University of Miami, Miami, FL, USA

    Mark S. Soloway

Authors
  1. Kishore Thekke Adiyat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Devendar Katkoori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mark S. Soloway
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Miller School of Medicine, Dept. Urology & Cell Biology & Anatomy, University of Miami, NW. 10th Avenue 1400, Miami, 33136, Florida, USA

    Vinata B. Lokeshwar

  2. , Department of Urology and Urologic Oncol, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover, 30625, Germany

    Axel S. Merseburger

  3. Klinik für Urologie und Kinderurologie, Universitätsklinikum Schleswig-Holstein, Arnold-Heller-Str. 7, Kiel, 24105, Germany

    Stefan H. Hautmann

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Adiyat, K.T., Katkoori, D., Soloway, M.S. (2011). Intravesical Chemotherapy. In: Lokeshwar, V., Merseburger, A., Hautmann, S. (eds) Bladder Tumors:. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-60761-928-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-928-4_13

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-927-7

  • Online ISBN: 978-1-60761-928-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation